Open AccessInterazioni farmacologiche degli inibitori delle integrasi tra le persone anziane che vivono con HIV.
Author(s) -
Hongmei Wang,
et al.
Publication year - 2022
Publication title -
journal of hiv and ageing
Language(s) - Italian
Resource type - Journals
eISSN - 2499-5819
pISSN - 2499-3638
DOI - 10.19198/jha31533
Subject(s) - dolutegravir , raltegravir , elvitegravir , human immunodeficiency virus (hiv) , integrase , medicine , pharmacology , antiretroviral therapy , virology , viral load
The advancement of Human Immunodeficiency Virus (HIV) treatment improves the life expectancy of HIV-positive individuals. People living with HIV have more polypharmacy and drug-drug interactions than those without HIV. Integrase strand transfer inhibitors (INSTIs) are the newest class commonly used for HIV treatment. There are five INSTIs currently approved by the Food and Drug Administration, including raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir. INSTIs class contributes to better safety and efficacy profile, making them the preferred or recommended antiretroviral regimens in HIV treatment guidelines worldwide. Despite the shared mechanism of action, INSTIs differ in pharmacokinetics, contributing to different drug-drug interactions. This review summarized the potential drug interactions of INSTIs and the management of the drug interactions in clinical practice.